Uncategorized
Triple therapy with zeaxanthin reduces AMD treatment burden, cost
Triple combination therapy for neovascular age-related macular degeneration was more cost-effective and dosed less frequently with supplemental zeaxanthin than without the supplement, according to a study.The comparative interventional study included 543 eyes of 424 patients with subfoveal choroidal neovascularization due to AMD. All eyes underwent triple combination therapy with reduced-fluence photodynamic therapy with verteporfin, intravitreal Avastin (bevacizumab, Genentech) and intravitreal dexamethasone.